Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke P Akard

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
The New England Journal of Medicine|October 26, 2010
Second-generation BCR-ABL kinase inhibitors in CMLLuke P Akard
Clinical Lymphoma, Myeloma & Leukemia|August 11, 2018
Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase InhibitorsPradnya Chopade, Luke P Akard
Leukemia & Lymphoma|August 27, 2016
Rationale and motivating factors for treatment-free remission in chronic myeloid leukemiaLauren Caldemeyer, Luke P Akard
Leukemia & Lymphoma|January 5, 2016
Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phaseLuke P Akard, Dale Bixby
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2011
Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitionersLuke P Akard, Y Lynn Wang
Clinical Advances in Hematology & Oncology : H&O|December 29, 2012
Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemiaElias J Jabbour, Dale Bixby, Luke P Akard
Transfusion|December 2, 2008
Starting granulocyte-colony-stimulating factor (filgrastim) early after autologous peripheral blood progenitor cell transplantation leads to faster engraftment without increased resource utilizationJames M Thompson, Pam Carlton, Luke P Akard, et al.
Journal of Cellular and Molecular Medicine|March 24, 2005
Transplantation of hematopoietic stem cells from the peripheral bloodJan Jansen, Susan Hanks, James M Thompson, et al.
American Journal of Hematology|December 21, 2004
Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplantMaureen A Cooper, Luke P Akard, James M Thompson, et al.
Journal of Oncology Practice|March 12, 2015
Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemiaStuart L Goldberg, Luke P Akard, Michael J Dugan, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|October 26, 2010
Second-generation BCR-ABL kinase inhibitors in CMLLuke P Akard
Clinical Lymphoma, Myeloma & Leukemia|August 11, 2018
Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase InhibitorsPradnya Chopade, Luke P Akard
Leukemia & Lymphoma|August 27, 2016
Rationale and motivating factors for treatment-free remission in chronic myeloid leukemiaLauren Caldemeyer, Luke P Akard
Leukemia & Lymphoma|January 5, 2016
Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phaseLuke P Akard, Dale Bixby
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2011
Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitionersLuke P Akard, Y Lynn Wang
Clinical Advances in Hematology & Oncology : H&O|December 29, 2012
Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemiaElias J Jabbour, Dale Bixby, Luke P Akard
Transfusion|December 2, 2008
Starting granulocyte-colony-stimulating factor (filgrastim) early after autologous peripheral blood progenitor cell transplantation leads to faster engraftment without increased resource utilizationJames M Thompson, Pam Carlton, Luke P Akard, et al.
Journal of Cellular and Molecular Medicine|March 24, 2005
Transplantation of hematopoietic stem cells from the peripheral bloodJan Jansen, Susan Hanks, James M Thompson, et al.
American Journal of Hematology|December 21, 2004
Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplantMaureen A Cooper, Luke P Akard, James M Thompson, et al.
Journal of Oncology Practice|March 12, 2015
Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemiaStuart L Goldberg, Luke P Akard, Michael J Dugan, et al.
Pageof 3